Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Non-Current AssetsPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Accumulated Expenses (2016 - 2025)

Fennec Pharmaceuticals' Accumulated Expenses history spans 15 years, with the latest figure at $5.6 million for Q4 2025.

  • For the quarter ending Q4 2025, Accumulated Expenses rose 343.35% year-over-year to $5.6 million, compared with a TTM value of $5.6 million through Dec 2025, up 343.35%, and an annual FY2025 reading of $5.6 million, up 343.35% over the prior year.
  • Accumulated Expenses for Q4 2025 was $5.6 million at Fennec Pharmaceuticals, up from $1.3 million in the prior quarter.
  • The five-year high for Accumulated Expenses was $5.6 million in Q4 2025, with the low at $171000.0 in Q2 2021.
  • Average Accumulated Expenses over 5 years is $1.4 million, with a median of $1.1 million recorded in 2023.
  • Year-over-year, Accumulated Expenses crashed 60.69% in 2021 and then surged 368.85% in 2023.
  • Tracing FENC's Accumulated Expenses over 5 years: stood at $860000.0 in 2021, then tumbled by 69.77% to $260000.0 in 2022, then surged by 368.85% to $1.2 million in 2023, then grew by 4.27% to $1.3 million in 2024, then soared by 343.35% to $5.6 million in 2025.
  • Per Business Quant, the three most recent readings for FENC's Accumulated Expenses are $5.6 million (Q4 2025), $1.3 million (Q3 2025), and $2.2 million (Q2 2025).